Arcutis Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2836 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 6th, 2026 2:00 pm
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In? - Nov 6th, 2026 3:14 am
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch? - Nov 5th, 2026 2:22 pm
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary - Nov 5th, 2026 6:30 am
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis - Nov 5th, 2026 6:00 am
Arcutis Biotherapeutics Q3 Earnings Call Highlights - Nov 4th, 2026 5:14 pm
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates - Nov 4th, 2026 2:15 pm
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update - Nov 4th, 2026 2:00 pm
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy? - Oct 29th, 2026 7:00 am
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth - Oct 28th, 2026 7:00 am
Arcutis Appoints Rob Scott, MD to Board of Directors - Oct 28th, 2026 7:00 am
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Oct 27th, 2026 2:00 pm
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 - Oct 21st, 2026 2:00 pm
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb - Oct 19th, 2026 8:37 pm
Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock - Oct 19th, 2026 5:21 pm
Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027 - Oct 19th, 2026 11:13 am
2 Stocks That Could Soar in Q4 - Oct 12th, 2026 5:05 am
Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value? - Oct 9th, 2026 11:14 pm
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - Oct 9th, 2026 6:00 am
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award - Oct 6th, 2026 6:19 am